Does Insurance Cover Mounjaro? 2026 Guide

Section 1: What Is Mounjaro Approved For?

Mounjaro (tirzepatide 2.5 mg through 15 mg once-weekly injection) has one FDA-approved indication:

• ✓
  Type 2 diabetes: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Mounjaro is a dual GIP/GLP-1 receptor agonist — the first in its class — that acts on two gut hormone receptors involved in blood sugar regulation and appetite.
• ⚠
  Not FDA-approved for weight loss: Mounjaro does not carry a weight-management indication. Zepbound (tirzepatide at the same doses) is the FDA-approved formulation for chronic weight management. Most insurers will not cover Mounjaro for off-label weight loss, and prescriptions submitted with weight-loss diagnosis codes will typically be denied.

Section 2: How Coverage Is Typically Structured

Formulary tier placement

Mounjaro typically appears on Tier 3 or Tier 4 (specialty tier) on commercial formularies. Across major plan administrators including Aetna, BCBS, Cigna, UnitedHealthcare, Humana, and Anthem, Mounjaro is commonly covered for diabetes when prior authorization criteria are met. Some plans list it as "non-preferred" within the specialty tier, which results in higher cost-sharing. Medicaid covers Mounjaro in most states for diabetes, though state-specific prior authorization rules apply.

Prior authorization criteria

Prior authorization is required by most plans. Standard documentation requirements for the diabetes indication include:

• Confirmed Type 2 diabetes diagnosis (ICD-10 code E11.x)
• Recent A1C results (typically above 7.0% or 7.5% depending on plan)
• Documentation of prior diabetes medication trials, most commonly metformin
• Clinical notes documenting inadequate glycemic control on prior therapy
• Prescriber letter of medical necessity
• Patient insurance and demographic information

Standard PA decisions take 3 to 14 business days. Most plans authorize Mounjaro for 6 to 12 months, after which reauthorization is required. Reauthorization typically requires evidence of ongoing clinical benefit (A1C improvement or maintenance).

Step therapy

Step therapy for Mounjaro in the diabetes setting most commonly requires a documented trial of metformin. Some plans require a trial of a second-line agent (sulfonylurea, DPP-4 inhibitor, or SGLT-2 inhibitor) before approving Mounjaro. Patients with contraindications to required step agents — such as kidney disease precluding metformin or SGLT-2 inhibitors — may request a step therapy exception with appropriate clinical documentation. Medicare Part D plans typically cover Mounjaro for diabetes with prior authorization, and step therapy requirements vary by plan.

Section 3: Typical Out-of-Pocket Cost with Insurance

The list price for Mounjaro is approximately $1,080 per month before insurance. Your actual cost depends on your plan's tier placement and deductible structure:

Section 4: Common Reasons for Denial and How to Appeal

Common denial reasons

• 1
  Off-label indication: Prescription submitted with a weight-loss diagnosis code. Plans only cover Mounjaro for Type 2 diabetes. Confirm the correct ICD-10 code (E11.x) is used.
• 2
  Step therapy not completed: No documented prior trial of metformin or other required first-line diabetes medications, or the trial duration was insufficient.
• 3
  Inadequate clinical documentation: Missing or outdated A1C results, incomplete medical records, or unsigned prior authorization forms.
• 4
  Formulary non-preferred tier: Some plans list Mounjaro as non-preferred, requiring additional justification that a preferred-tier GLP-1 is not appropriate for this patient.
• 5
  Expired authorization: Reauthorization was not submitted before the prior PA period ended. Claims filled after expiration are denied automatically.

How to appeal

1. Obtain the denial letter and identify the specific reason code.
2. Confirm that the correct diabetes ICD-10 code was used on the original submission.
3. Work with your prescriber to prepare a medical necessity appeal letter addressing the denial reason.
4. Gather supporting documentation: A1C history, diabetes treatment timeline, comorbidities, and evidence of inadequate glycemic control on prior agents.
5. Submit the complete appeal packet within your plan's deadline (typically 60 to 180 days from denial).
6. Request a peer-to-peer review between your physician and the insurer's medical director — this can significantly improve the outcome of a medical necessity denial.

Section 5: Eli Lilly Savings Programs for Mounjaro

Eli Lilly operates savings programs that can substantially reduce Mounjaro costs for eligible patients:

Section 6: If Your Insurance Does Not Cover Mounjaro

If coverage is denied or not available, telehealth providers offer GLP-1 medication access through licensed prescribers with direct home delivery.

Advertising disclosure: The telehealth options below are paid sponsors. We may earn a commission when you sign up. This does not affect your pricing. Listing order does not imply medical recommendation. Always consult a licensed healthcare provider.

Section 7: Frequently Asked Questions